NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
The last earnings update was 14 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NeuBase Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NeuBase Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
NeuBase Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if NeuBase Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NeuBase Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
NeuBase Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
NeuBase Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
NeuBase Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
NeuBase Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 172.4x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Dietrich A. Stephan, Ph.D., is the Founder of Silicon Valley Biosystems, Inc., and serves as its Chief Executive Officer and President. Dr. Stephan serves as Scientist in Chief and Founding Member at Lifecode, Inc. He serves as an Advisor of GnuBIO, Inc. He is a Human Geneticist, who works to understand the root causes of common human diseases. He oversees all discovery research and is the Director and Senior Investigator of the Neurogenomics Division at the Translational Genomics Research Institute. He has identified genes that predispose to disorders such as autism, exercise-induced heart attacks and sudden infant death syndrome and contributed to understanding a multitude of common “complex genetic“disorders such as Alzheimer's disease. He co-founded DiaVacs, Inc. He was a Co-Founder, Chief Science Officer and Observer of Navigenics, Inc. He serves as the Chairman of Peptilogics, Inc. He Founded NeuBase Therapeutics, Inc. and has been its President, Chief Executive Officer and Chairman since July 12, 2019. He serves as the Chairman of the National Institutes of Health (NIH) Neuroscience Microarray Consortium and held faculty appointments at Johns Hopkins University, the National Human Genome Research Institute of the NIH, the University of Arizona, Arizona State University, George Washington University and the Children's National Medical Center in Washington DC. He serves as an External Director at Parabase Genomics, Inc. He serves as a Director of Whole Biome, Inc. and DiaVacs, Inc. He serves as a Member of Scientific Advisory Board at Genia Technologies, Inc. He serves as a Director and Member of Scientific Advisory Board at CereDx Inc. He has published extensively in journals such as Science, the Proceedings of the National Academy of Sciences, Nature Genetics and the New England Journal of Medicine. He served as a Director and Member of Scientific Advisory Board at Navigenics, Inc. Dr. Stephan received his B.A. at Carnegie-Mellon University, his Ph.D. at the University of Pittsburgh and trained as a Fellow at the National Human Genome Research Institute of the NIH.
Dietrich's compensation has increased whilst company is loss making.
Dietrich's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the NeuBase Therapeutics management team is less than 2 years, this suggests a new team.
CFO, Treasurer & Secretary
Chief Scientific Officer
Consulting Chief Medical Officer
Chief of Preclinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the NeuBase Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.